Biogen Tecfidera US win: Broad, clean label; price pending
This article was originally published in Scrip
The much-anticipated US approval for Biogen Idec's new multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate), previously known as BG-12, came not only one day ahead of its 28 March Prescription Drug User Fee Act action date, but with broad, clean labeling – generating a sigh of relief on Wall Street, as shares of the firm climbed 3% in the short half-hour between the US FDA's notice and the bell.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.